Effect of piperine supplement in patients with non alcoholic fatty liver disease

Investigation of the effect of piperine supplement on anthropometric indices, ultrasonographic findings, biochemical parameters and quality of life in patients with nonalcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180802040678N2

Enrollment

Registered

2019-08-13

Start date

2019-08-11

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Alcoholic Fatty Liver Disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Administration of Piperine 5mg supplement daily for three months. Intervention 2: Control group: Administration of placebo for three months.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Grade 2 and 3 non-alcoholic fatty liver ALT levels upper than 1.5 times the normal upper limit

Exclusion criteria

Exclusion criteria: Chronic liver disease, diabetes, malignancy, hereditary diseases that affect the liver such as iron and copper storage disorder, untreated hypothyroidism, autoimmune disease, pregnancy, lactation, alcoholic fatty liver disease, consumption Alcohol, hepatitis Hypolipidemic and anti-inflammatory agents Bariatrics surgery in last year 43/5000Heavy diet to lose weight in the last 3 months Increase in fatty liver grade grade based on ultrasonographic findings during the study period Weight loss more than 10% during the study Discontent to continuation the study Not taking more than 10% of supplement

Design outcomes

Primary

Measure	Time frame
Fattly Liver Grading. Timepoint: Before and after intervention. Method of measurement: Ultrasonography.;Quality of Life. Timepoint: Before and after intervention. Method of measurement: SF-36, CLDQ, and Disease Symptom Index 2.0 questionnaires.;Anthropometric indices. Timepoint: Before and after intervention. Method of measurement: Body weight and Body Mass Index.;Biochemical parameters. Timepoint: Before and after intervention. Method of measurement: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Bilirubin Total and Direct, Fasting Blood Suger, Triglyceride, LDL, HDL, VLDL, Hs-CRP, Total Cholesterol, Albumin, Count Blood Cells, HbA1C, HOMA-IR, Fecal Calprotectin.	—

Measure

Time frame

Fattly Liver Grading. Timepoint: Before and after intervention. Method of measurement: Ultrasonography.;Quality of Life. Timepoint: Before and after intervention. Method of measurement: SF-36, CLDQ, and Disease Symptom Index 2.0 questionnaires.;Anthropometric indices. Timepoint: Before and after intervention. Method of measurement: Body weight and Body Mass Index.;Biochemical parameters. Timepoint: Before and after intervention. Method of measurement: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Bilirubin Total and Direct, Fasting Blood Suger, Triglyceride, LDL, HDL, VLDL, Hs-CRP, Total Cholesterol, Albumin, Count Blood Cells, HbA1C, HOMA-IR, Fecal Calprotectin.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoud Nouri-Vaskeh

Tabriz University of Medical Sciences

mnvaske@gmail.com+98 41 3325 9778

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026